This is a routine corporate presentation update with no new financial data or material changes. The key catalysts remain the Phase 2 topline data readouts for tibulizumab in HS (Q4 2026) and SSc (1H 2027). Monitor for enrollment completion announcements and any early efficacy signals from the ongoing trials.
Price Chart
Executive Summary
Zura Bio filed an 8-K furnishing an updated corporate presentation (Exhibit 99.1) for investor meetings. The presentation highlights tibulizumab, a first-in-class bispecific antibody targeting IL-17 and BAFF, with Phase 2 data readouts expected in Q4 2026 (hidradenitis suppurativa) and 1H 2027 (systemic sclerosis). The company reported ~$225.6M in cash as of March 31, 2026, with a February 2026 public offering expected to fund operations through at least end of 2028.
Key Facts
- Tibulizumab is a first-in-class bispecific antibody targeting IL-17 and BAFF pathways
- Phase 2 HS trial (TibuSHIELD) enrollment completed with 247 participants; topline data expected Q4 2026
- Phase 2 SSc trial (TibuSURE) on track to complete enrollment early July 2026, exceeded 80 participant target; topline data expected 1H 2027
- ~$225.6M in cash and cash equivalents as of March 31, 2026
- February 2026 public offering expected to fund operations through at least end of 2028
- ~124M shares outstanding as-converted as of March 31, 2026
- Plan to initiate Phase 2 study in a third immune-mediated indication by year-end 2026
Financial Impact
No new financial results reported. Cash position of ~$225.6M as of March 31, 2026, with February 2026 public offering expected to fund operations through at least end of 2028.
Risk Factors
- Tibulizumab is an investigational agent with no approved products; clinical trial failure risk is high
- Phase 2 data readouts in Q4 2026 and 1H 2027 are binary catalysts that could significantly impact stock price
- Competitive landscape includes multiple approved and late-stage therapies for HS and SSc
- Company has no revenue and relies on capital markets for funding; ~124M shares outstanding with potential dilution from options and RSUs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-079538 |
| Document: tm2619483d1_8k.htm | 0001104659-26-079538 |
| Document: 0001104659-26-079538-index-headers.html | 0001104659-26-079538 |
| Document: 0001104659-26-079538-index.html | 0001104659-26-079538 |
| Document: 0001104659-26-079538.txt | 0001104659-26-079538 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 10w ago | 8-K | $5.68 $4.93 | ▼ −13.20% | ▼ −11.23% | $3.56 (−37.41%) |
Aug 11, 2026 10w ago | 8-K | $5.56 $5.71 | ▲ +2.70% | ▲ +3.76% | $3.56 (−36.06%) |
Jul 1, 2026 16w ago | 8-K | $5.01 $5.31 | ▲ +6.09% | ▲ +8.28% | $3.56 (−28.97%) |
Jun 18, 2026 18w ago | 8-K | $4.23 $5.45 | ▲ +28.84% | ▲ +28.99% | $3.56 (−15.96%) |
May 7, 2026 24w ago | 8-K | $4.54 $3.86 | ▼ −14.98% | ▼ −18.11% | $3.56 (−21.70%) |
Mar 5, 2026 33w ago | 8-K | $6.76 $6.03 | ▼ −10.80% | ▼ −7.01% | $3.56 (−47.41%) |
Feb 26, 2026 34w ago | 8-K | $6.77 $6.04 | ▼ −10.78% | ▼ −4.38% | $3.56 (−47.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers